
Quest Diagnostics (DGX) Stock Forecast & Price Target
Quest Diagnostics (DGX) Analyst Ratings
Bulls say
Quest Diagnostics demonstrates a strong financial performance, highlighted by a 13.1% year-over-year revenue growth to $2.82 billion, surpassing internal expectations and consensus estimates. The company has seen remarkable expansion in the physician channel, with growth of approximately 20% year-over-year, supported by increased demand for tests and healthy trends among enterprise accounts, as well as a significant 30-40% increase in consumer-initiated testing. Additionally, the total volume of tests conducted grew by 16.3% year-over-year, indicating robust operational momentum and ongoing strength in advanced diagnostics markets.
Bears say
The financial outlook for Quest Diagnostics appears negative, driven by a reported revenue per requisition decline of 0.4%, which fell short of expectations, raising concerns about growth in this key metric. Additionally, the anticipated impact of the Protecting Access to Medicare Act (PAMA) may result in a significant headwind of approximately $100 million, with uncertainty surrounding legislative outcomes further complicating the company's revenue prospects. Furthermore, the integration of the LifeLabs acquisition has not yet yielded the expected benefits, contributing to a cautious revenue trajectory despite some strength observed in organic revenue growth.
This aggregate rating is based on analysts' research of Quest Diagnostics and is not a guaranteed prediction by Public.com or investment advice.
Quest Diagnostics (DGX) Analyst Forecast & Price Prediction
Start investing in Quest Diagnostics (DGX)
Order type
Buy in
Order amount
Est. shares
0 shares